Natera, Inc. (NTRA)Healthcare | Diagnostics & Research | Austin, United States | NasdaqGS
272.89 USD
+2.94
(1.089%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 272.30 -0.59 (-0.590%) ⇩ (July 13, 2026, 7:50 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 2:51 a.m. EDT
Natera offers a compelling high-growth healthcare narrative backed by robust revenue expansion and a fortress-like balance sheet, though profitability remains elusive. The stock has rallied significantly over the past month, trading near its 52-week highs, which creates a crowded trade at these valuations. While analysts maintain a strong buy stance, the disconnect between negative earnings and positive cash flow warrants caution. Options activity reveals a bifurcated sentiment: traders are betting on a breakout above $300 in the near term while hedging against a drop below $200 in the longer term. This divergence suggests the market is pricing in a binary outcome—either a successful regulatory expansion or a stagnation in growth. Investors should view this as a speculative growth play rather than a value investment, given the lack of dividends and reliance on future earnings to justify the premium. |
| Model | MAE |
|---|---|
| MSTL_66_126 ✓ | 0.073769 |
| AutoTheta | 0.080615 |
| MSTL_126 | 0.080843 |
| AutoETS | 0.085669 |
| AutoARIMA | 0.085669 |
| MSTL | 0.086019 |
| MSTL_66 | 0.095478 |
Forecast horizon: 60 days | Selected: MSTL_66_126
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 25.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.004 |
| Excess Kurtosis | -0.16 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 13.533 |
| Revenue per Share | 18.069 |
| Market Cap | 39,082,045,440 |
| Forward P/E | -1333.19 |
| Beta | 1.51 |
| Profit Margins | -9.05% |
| Website | https://www.natera.com |
As of July 11, 2026, 2:51 a.m. EDT: Near-term call activity clusters around the $250 to $300 range, indicating bullish bets on a breakout, while deeper-dated put walls at $180 to $210 suggest a perceived downside floor. Implied volatility is elevated at extreme strikes, reflecting uncertainty around regulatory milestones and earnings execution.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.70660007 |
| Address1 | 13,011 McCallen Pass |
| Address2 | Building A Suite 100 |
| All Time High | 288.04 |
| All Time Low | 6.52 |
| Ask | 287.31 |
| Ask Size | 2 |
| Audit Risk | 1 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,714,770 |
| Average Daily Volume3 Month | 1,580,159 |
| Average Volume | 1,580,159 |
| Average Volume10Days | 1,714,770 |
| Beta | 1.505 |
| Bid | 245.62 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 12.429 |
| City | Austin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 272.89 |
| Current Ratio | 2.959 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 273.335 |
| Day Low | 261.63 |
| Debt To Equity | 13.533 |
| Display Name | Natera |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -267,576,992 |
| Ebitda Margins | -0.10699 |
| Enterprise To Ebitda | -142.89 |
| Enterprise To Revenue | 15.288 |
| Enterprise Value | 38,234,193,920 |
| Eps Current Year | -1.70384 |
| Eps Forward | -0.20469 |
| Eps Trailing Twelve Months | -1.64 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 225.5186 |
| Fifty Day Average Change | 47.371414 |
| Fifty Day Average Change Percent | 0.21005547 |
| Fifty Two Week Change Percent | 70.66 |
| Fifty Two Week High | 288.04 |
| Fifty Two Week High Change | -15.149994 |
| Fifty Two Week High Change Percent | -0.052596837 |
| Fifty Two Week Low | 131.811 |
| Fifty Two Week Low Change | 141.07901 |
| Fifty Two Week Low Change Percent | 1.0703129 |
| Fifty Two Week Range | 131.811 - 288.04 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,435,757,400,000 |
| Float Shares | 139,083,618 |
| Forward Eps | -0.20469 |
| Forward P E | -1,333.1869 |
| Free Cashflow | 136,918,256 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 6,135 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.65066004 |
| Gross Profits | 1,627,248,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02984 |
| Held Percent Institutions | 0.95958 |
| Implied Shares Outstanding | 143,215,382 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas. |
| Long Name | Natera, Inc. |
| Market | us_market |
| Market Cap | 39,082,045,440 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_27603970 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -226,315,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 38,660,992,370 |
| Number Of Analyst Opinions | 21 |
| Open | 266.97 |
| Operating Cashflow | 211,020,000 |
| Operating Margins | -0.123900004 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 980 9190 |
| Post Market Change | -0.59002686 |
| Post Market Change Percent | -0.21621417 |
| Post Market Price | 272.3 |
| Post Market Time | 1,783,986,649 |
| Previous Close | 269.95 |
| Price Eps Current Year | -160.16176 |
| Price Hint | 2 |
| Price To Book | 21.955912 |
| Price To Sales Trailing12 Months | 15.627024 |
| Profit Margins | -0.09049 |
| Quick Ratio | 2.697 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 2.94 |
| Regular Market Change Percent | 1.08909 |
| Regular Market Day High | 273.335 |
| Regular Market Day Low | 261.63 |
| Regular Market Day Range | 261.63 - 273.335 |
| Regular Market Open | 266.97 |
| Regular Market Previous Close | 269.95 |
| Regular Market Price | 272.89 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,483,872 |
| Return On Assets | -0.09117 |
| Return On Equity | -0.15019 |
| Revenue Growth | 0.388 |
| Revenue Per Share | 18.069 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 143,215,382 |
| Shares Percent Shares Out | 0.040599998 |
| Shares Short | 5,820,616 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 3,614,976 |
| Short Name | Natera, Inc. |
| Short Percent Of Float | 0.0419 |
| Short Ratio | 3.66 |
| Source Interval | 15 |
| State | TX |
| Symbol | NTRA |
| Target High Price | 325.0 |
| Target Low Price | 193.0 |
| Target Mean Price | 271.2381 |
| Target Median Price | 275.0 |
| Total Cash | 1,087,932,032 |
| Total Cash Per Share | 7.596 |
| Total Debt | 240,080,992 |
| Total Revenue | 2,500,926,976 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.64 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 213.1547 |
| Two Hundred Day Average Change | 59.73532 |
| Two Hundred Day Average Change Percent | 0.280244 |
| Type Disp | Equity |
| Volume | 1,483,872 |
| Website | https://www.natera.com |
| Zip | 78,753 |